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Patients with acute heart failure (AHF) require urgent in-hospital treatment for relief of symptoms. The main reason for hospitalization is con-
gestion, rather than low cardiac output. Although congestion is associated with a poor prognosis, many patients are discharged with persistent
signs and symptoms of congestion and/or a high left ventricular filling pressure. Available data suggest that a pre-discharge clinical assessment of
congestion is often not performed, and even when it is performed, it is not done systematically because no method to assess congestion prior to
discharge has been validated. Grading congestion would be helpful for initiating and following response to therapy. We have reviewed a variety of
strategies to assess congestion which should be considered in the care of patients admitted with HF. We propose a combination of available
measurements of congestion. Key elements in the measurement of congestion include bedside assessment, laboratory analysis, and dynamic
manoeuvres. These strategies expand by suggesting a routine assessment of congestion and a pre-discharge scoring system. A point system is
used to quantify the degree of congestion. This score offers a new instrument to direct both current and investigational therapies designed
to optimize volume status during and after hospitalization. In conclusion, this document reviews the available methods of evaluating congestion,
provides suggestions on how to properly perform these measurements, and proposes a method to quantify the amount of congestion present.
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Introduction
Acute heart failure (AHF) is defined as new-onset or worsening HF
signs and symptoms requiring urgent therapy, most commonly in
the hospital setting.1– 3 Signs and symptoms usually improve mark-
edly during hospitalization, however mortality during admission
remains high, ranging from 5 to 15% or more.2,4 –8 Many patients
are managed by non-specialists and most patients have one or
more serious co-morbid conditions that contribute to poor
outcome and exclude patients from participation in clinical trials.
Of those patients who survive to discharge, a further 10–15%
will die within 6–12 weeks and about one-third will be re-admitted
for a variety of reasons; often HF.2,4,5
Available data suggest that the main reason for hospitalization
for worsening HF is related to the symptoms (dyspnoea or breath-
lessness) of congestion, manifested also by signs [e.g. jugular
venous distension (JVD), rales, and oedema] of congestion,
rather than low cardiac output.4,5,9– 11 Although congestion is
the main reason for hospitalization, many patients are discharged
without losing body weight and with persistent signs of conges-
tion.10,12 This may be a particular problem in US hospitals where
admissions are much shorter than in Europe. Congestion is associ-
ated with a poor prognosis and is an important target for
therapy.13,14
To the best of our knowledge, no systematic method to assess
congestion prior to discharge has been proposed by available
guidelines or research studies.15– 17 This document reviews the
available methods of evaluating congestion, provides suggestions
on how to properly perform these measurements, and proposes
a method to quantify the amount of congestion present.
Congestion in acute heart failure
Pathophysiology
Clinical congestion in HF is defined as a high left ventricular dias-
tolic pressure (LVDP) associated with signs and symptoms of HF
such as dyspnoea, rales, and oedema. Elevation of LVDP in HF
patients without overt clinical congestion has been termed
‘haemodynamic congestion’.12 Often, haemodynamic congestion
precedes clinical congestion by days or even weeks.18– 22 Thus,
clinical congestion may be the ‘tip of the iceberg’ of the haemo-
dynamic derangements that precede symptoms (Figure 1). In fact,
in chronic HF, even severe haemodynamic congestion rarely
causes rales and/or radiographic pulmonary oedema.23,24 This
may be related to several adaptive pathophysiological changes
such as increases in alveolar capillary membrane thickness,
increased lymphatic drainage, and/or pulmonary hypertension.
Theoretically, haemodynamic congestion may contribute to the
progression of HF by further activating neurohormones and by
causing subendocardial ischaemia, resulting in myocardial necro-
sis/apoptosis and/or secondary mitral insufficiency by its effects
on LV geometry (changing it from an ellipsoid to a sphere).25–28
In addition, elevated right atrial pressure may contribute to the
cardio-renal syndrome through reduction of the perfusion gradient
across the kidneys.29– 32
Prognosis
Clinical congestion has prognostic importance in HF patients. In a
retrospective analysis of the Acute and Chronic Therapeutic
Impact of a Vasopressin-2 Antagonist in Congestive Heart Failure
(ACTIV in CHF) trial, patients with dyspnoea, oedema, and JVD on
admission had a two- to three-fold increase in 60-day mortality com-
pared with those without these features.33 Retrospective analysis of
the Studies of Left Ventricular Dysfunction (SOLVD) treatment trial
demonstrated that signs of congestion in patients with chronic HF
were associated with 15 and 43% relative increases in the risk of all-
cause death and HF hospitalization, respectively, during the mean
follow-up period of 32 months.13 In a cohort of 146 decompensated
HF patients, those with 0, 1–2, and≥3 residual symptoms or signs of
congestion (e.g. orthopnoea, JVD, oedema, weight gain, and new
increase in baseline diuretics) had 2-year survival rates of 87, 67,
and 41%, respectively.14 When patients admitted with HF were
characterized according to their haemodynamic profile, those with
evidence of congestion had higher rates of death or death plus
urgent transplantation than other clinical profiles.34 The Evaluation
Study of Congestive Heart Failure and Pulmonary Artery Catheter-
ization Effectiveness (ESCAPE) study found elevated pulmonary
capillary wedge pressure (PCWP) and reduced 6 min walk to be
the strongest independent predictors in post-discharge mortality
after hospitalization for worsened HF among all clinical, haemo-
dynamic, and laboratory variables studied.35 Several other studies
have also shown that patients with haemodynamic congestion have
poor outcomes.36– 38
Therapy
Since congestion is also related to water and sodium retention, the
main goal of therapy is to remove excess intravascular and extra-
vascular fluid without further activation of neurohormones and
without worsening renal function. In addition, these therapies
should not cause myocardial damage. At present, the most widely
used and relatively effective therapies for fluid removal are non-
Figure 1 Pathophysiology of congestion. RV, right ventricular;
RA, right atrial; PA, pulmonary artery; PCWP, pulmonary capillary
wedge pressure; LA, left atrial; LV, left ventricular; LVDP, left ven-
tricular diastolic pressure; JVD, jugular venous distension.
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potassium sparing diuretics. Their use, however, has been associated
with significant side effects (i.e. hypokalaemia, activation of neuro-
hormones, arterial vasoconstriction, and worsening renal func-
tion).39– 42 Worsening renal function occurs in 34% of hospitalized
patients and is associated with poor prognosis.43 Ultrafiltration
appears to remove fluid and reduce hospitalizations; however, this
fluid removal may or may not be associated with improved survival.44
Vasopressin antagonists remove electrolyte-free water by blocking
vasopressin receptors in the distal nephron. Analysis of the Efficacy
of Vasopressin Antagonism in Heart Failure Outcome Study With
Tolvaptan (EVEREST) trial, which studied the effects of tolvaptan
vs. placebo in patients hospitalized with worsening HF and LV ejec-
tion fraction (LVEF) ≤40%, demonstrated a significant reduction in
symptoms of congestion due to loss in body fluid with tolvaptan;
however, mortality and hospitalizations were unaffected when com-
pared with placebo.45,46 Moreover, a drug that had a favourable
effect on renal function (rolofylline, an adenosine antagonist) did
not have a beneficial long-term effect in AHF.47,48 It is possible that
the best way to keep off excess fluid to avoid decompensation is
to improve overall cardiac function using evidence-based therapies
such as beta-blockers, angiotensin-converting enzyme inhibitors,
aldosterone receptor antagonists, and cardiac resynchronization
therapy, although diuretics may still be necessary to maintain relief
from congestion despite these measures.49
Assessment of congestion
Available guidelines recommend treatment to improve symptoms
and signs of congestion and that patients achieve near-optimal
volume status prior to discharge; however, there is no established
algorithm for the assessment of congestion.16 Currently, the gold
standard for evaluating haemodynamic congestion in HF patients
is cardiac catheterization to measure right atrial pressure and
PCWP.50 However, the invasive nature of catheterization limits
its routine use in practice. No single non-invasive test can accu-
rately detect haemodynamic congestion, and the ability to detect
congestion by haemodynamic measurements remains a diagnostic
challenge because it usually precedes clinical symptoms. Relying
on a limited set of physical examination findings and/or radio-
graphic signs has met with low sensitivity and poor predictive
value. In a series of 50 patients with chronic HF, physical signs of
congestion [rales, oedema, and elevated jugular venous pressure
(JVP)] were absent in 42% of the patients with a measured
PCWP ≥22 mmHg and the combination of these signs showed
only a 58% sensitivity in detecting elevated PCWP.24 In another
study of 52 patients with chronic HF referred for evaluation for
heart transplantation, physical signs (orthopnoea, oedema, rales,
third heart sound, and elevated JVP) or radiographic signs (cardio-
megaly, vascular redistribution, and interstitial and alveolar
oedema) had poor predictive value for identifying patients with
elevated PCWP.51 In another study of 52 chronic HF patients,
the presence of JVD, when measured carefully, had the best com-
bination of sensitivity (81%), specificity (80%), and predictive accu-
racy (81%) for detection of an elevation in PCWP (≥18 mmHg).52
In the ESCAPE trial, JVD and orthopnoea were the only two find-
ings from history and physical examination associated with an elev-
ated PCWP.53
Proposed pre-discharge
assessment of congestion
There are several ways of assessing congestion, which have been
evaluated individually. Each measurement in isolation has diagnostic
limitations in sensitivity, specificity, and predictive value (Table 1).
However, no single study has assessed all of these measurements
simultaneously. A summary of the advantages and limitations of
different methods used for measuring congestion is presented in
Table 2.
Bedside assessment
Breathlessness/dyspnoea/orthopnoea
Given the dominance of dyspnoea as a presenting symptom, its
relief or improvement is an important marker of reduced conges-
tion. At the present time, however, there is no validated method of
assessing breathlessness/dyspnoea in HF patients. In the meantime,
a consensus proposal has been put forward to facilitate standard-
ization of measurement.54 Both a Likert scale and/or visual ana-
logue scale may be used to measure dyspnoea. The Likert and
the visual analogue scores are initially measured in the sitting pos-
ition (608) and then, if the patient is not already too breathless, in
the supine position (208) after at least 2 min if tolerated. Symptoms
should be measured on an absolute scale (e.g. I am very breathless
or not at all breathless) rather than a relative scale (e.g. do not ask
about whether symptoms have improved) since the latter may be
more difficult to interpret as it requires patients to remember their
symptomatic state at the time of presentation.
Paroxysmal nocturnal dyspnoea is a symptom that occurs during
sleep, causes the patient to wake up with severe breathlessness,
and is relieved by sitting upright. Paroxysmal nocturnal dyspnoea
is an important symptom which often precedes pulmonary
oedema by several nights/days. Similar symptoms can occur in
chronic obstructive pulmonary disease.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Diagnostic value of clinical markers of
congestion
Sign or symptom Sensitivity Specificity PPV NPV
Dyspnoea on exertion 66 52 45 27
Orthopnoea 66 47 61 37
Oedema 46 73 79 46
Resting JVD 70 79 85 62
S3 73 42 66 44
Chest X-ray
Cardiomegaly 97 10 61 —
Redistribution 60 68 75 52
Interstitial oedema 60 73 78 53
Pleural effusion 43 79 76 47
Adapted from Chakko et al.51 and Butman et al.52 JVD, jugular venous distension;
S3, third heart sound; PPV, positive predictive value; NPV, negative predictive
value. All numbers are expressed as percentages.
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Orthopnoea has been shown to correlate with high PCWP with
a sensitivity approaching 90%.34 Persistent orthopnoea was associ-
ated with a higher rate of hospitalization when patients were fol-
lowed up for 6 months after discharge.55 Orthopnoea can be
tested by asking the patient to lie supine for a defined period of
time (e.g. 2 min) while monitoring respiratory rate and breathless-
ness. Supine positioning results in the mobilization of fluid from
dependent venous reservoirs in the abdomen and the lower extre-
mities, which increases venous return (250–500 cc fluid) to the
thoracic compartment. As a result, pulmonary venous and capillary
pressures rise further, elevating already high right- and left-sided
filling pressures. This may result in interstitial pulmonary oedema,
reduced pulmonary compliance, increased airway resistance, and
dyspnoea. At the time of discharge, excluding those with
advanced/end-stage HF, patients should be able to lie supine or
with no more than one pillow (unless more pillows are necessary
for other medical conditions such as back pain or gastro-
oesophageal reflux) without developing breathlessness.
Dyspnoea and orthopnoea are symptoms that may or may not
be cardiac in origin. The severity of dyspnoea or orthopnoea may
reflect the rapidity of the rise in PCWP as well as its absolute value.
Further research in this area is needed, given the dominance of
breathlessness as a presenting complaint.54
Dyspnoea on exertion
Functional capacity has been shown to predict mortality and hos-
pitalizations in HF patients.56 As might be expected, dyspnoea on
exertion is the most common persisting symptom at discharge.10
Ideally, patients without locomotor problems should be able to
walk for at least 6 min on level ground without undue breathless-
ness and complete at least 200 m, without postural symptoms of
dizziness or light-headedness.
Rales or crepitations
Auscultation of rales may indicate fluid overload but is non-specific.
The absence of rales is not a sensitive marker of the absence of
congestion.51 Rales should be examined after the patient has
been asked to cough. If rales persist at the time of discharge, it
should be noted whether they are due to other conditions such
as pneumonia, interstitial fibrosis, chronic bronchitis, asthma, or
emphysema or whether persistent congestion due to HF remains.
Jugular venous pressure
Jugular venous pressure reflects right atrial pressure, which usually
indicates an elevated PCWP in patients with HF.57 When per-
formed properly and by experienced physicians, JVP estimation is
fairly accurate.53,58 Strategies to improve measurement have
been suggested.58,59 In some individuals with pulmonary hyperten-
sion or tricuspid regurgitation, a high JVP is required to maintain
adequate left-sided filling pressures, and normalizing JVP prior to
discharge is not in the patient’s interest.60 The hepato-jugular
reflux may also be used to assess elevated pressure and is both
sensitive and reliable.61,62 Measurement of JVP is often limited by
patient body habitus such as obesity or respiratory pathology.
Although there are limitations, JVP elevation is associated with
an increased risk for HF hospitalization, is a simple measurement
of congestion, and is thus a potential target to monitor
therapy.13 However, its use in multi-centre studies is not reliable
without adequate audit of clinical expertise in each centre.
Oedema
In HF patients, peripheral oedema is usually associated with a high
right atrial pressure that is most commonly due to left-sided HF.
Lower extremity oedema frequently improves or resolves with
diuretic therapy during hospitalization. Oedema may also redistri-
bute to dependent areas during hospital bed rest (i.e. sacral
oedema) and is commonly missed by a casual examination. Appar-
ent improvement without weight loss during hospitalization
suggests redistribution of fluids. Therefore, both the sacrum and
lower limbs should be examined and weight charts reviewed
prior to discharge.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 A summary of the advantages and limitations
of some of the available methods for measurement of
congestion
Measurement Advantages Limitations
Resting dyspnoea
and orthopnoea
Rapid assessment May be non-cardiac in
origin
Dyspnoea on
exertion
Provides
functional
information
May be non-cardiac in
origin
Rales Rapid assessment Not sensitive or specific
for congestion
Jugular venous
pressure
Good sensitivity
and specificity
Difficult to assess in
obesity; intraobserver
variation
Oedema Simple
measurement
May not represent
congestion; must
correlate with jugular
venous pressure
Body weight Simple
measurement
Fluctuations may not
represent changes in
intravascular volume
Serum sodium Predicts
outcomes
Urea nitrogen Predicts
outcomes
Natriuretic
peptides
Predict
outcomes
Do not change acutely
(B-type peptides);
elevations found in
other conditions such as
renal disease or
cirrhosis
Radiographic
congestion
Not sensitive or specific
Orthostatic testing Important guide
for therapy
Complex measurement
Valsalva manoeuvre Dependent on patient
effort; can require
specialized equipment
Sublingual
nitroglycerin
Impractical in most
patients
Portable ultrasound Evolving
technology
Requires training and
specialized equipment
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A major limitation in using oedema as a measurement of conges-
tion is that it may not be related to high filling pressures, but rather
reflect extravascular volume shifts resulting from low plasma
oncotic pressure, high vascular permeability, or both.24 An elev-
ated JVP improves the specificity of oedema as a sign of congestion.
Recognizing these limitations, at the time of discharge, patients
should have no more than trace oedema unless they have pre-
existing oedema of non-cardiac aetiology (e.g. liver cirrhosis,
venous insufficiency, renal failure, and hypoalbuminaemia).
Body weight
Congestion as a result of sodium and water retention in HF
patients is often manifested by an increase in body weight.
Although a change in body weight observed over time (weeks or
months) may be associated with other contributing factors such
as malnutrition and deconditioning (cardiac cachexia), daily vari-
ation most likely reflects changes in volume status. Thus, an
acute change in body weight is a reasonable marker of fluid
balance. Measurement of body weight should be performed as
consistently as possible (using a standardized scale, preferably
with a precision of 50 g, at the same time of the day, post-void,
prior to eating, prior to the medication dose, and with patients
wearing the same clothing). The scales should stand on a flat,
solid surface rather than carpets unless specifically designed for
use in that setting.
One limitation to body weight measurement is that fluctuations
may not always reflect changes in intravascular volume. For
example, in the EVEREST study, patients hospitalized for worsened
HF who were receiving the selective vasopressin-2 receptor antag-
onist tolvaptan had reduced body weight compared with those
receiving placebo, but there was no significant effect on peripheral
oedema45 Another difficulty with using body weight as a measure
of congestion is that the degree of absolute weight loss may not be
as important in patients with acute hypertensive HF because some
of these patients may be euvolaemic with pulmonary but not sys-
temic congestion as a result of volume redistribution.,11,52 Absol-
ute weight loss is more important in patients with profound
anasarca, who require more fluid removal than patients without.
Ideally, patients should be at ‘target’ or at least at lower body
weight compared with admission. However, adequate diuresis
may be prevented by worsening renal function and/or hypotension.
Laboratory and radiographic
assessment
Blood urea nitrogen
Fluid balance in HF involves a complex interaction between the
heart and the kidneys.32 In response to reduced cardiac output,
there is a release of neurohormones by the sympathetic nervous
system, renin–angiotensin–aldosterone system, and the arginine
vasopressin system. This promotes fluid retention by the kidneys,
as well as renal and systemic vasoconstriction. Renal dysfunction,
as measured by serum creatinine or estimated glomerular filtration
rate (GFR), consistently predicts poor outcomes in HF in the
chronic63,64 and acute65–68 settings.
Blood urea nitrogen (BUN in the USA and urea in Europe) has
been investigated as a potential prognostic marker [urea (in mmol/
L) ¼ BUN (in mg/dL of nitrogen)/2.8].
Urea is produced in the liver as the degradation product of pro-
teins and is filtered by the kidneys. Unlike creatinine, which is
actively secreted and not reabsorbed, 40–50% of the filtered
urea is reabsorbed, predominantly in the proximal tubule, parallel-
ing reabsorption of sodium and water. Increases in urea in HF may
reflect congestion and fluid retention, as well as cardiac and renal
dysfunction, whereas elevation in creatinine is more specific for
changes in GFR.69 Recently, BUN was found to be a better predic-
tor of outcome than creatinine or estimated GFR in AHF.70–73
Elevations in BUN disproportionate to the rise in creatinine
(20:1 for BUN vs. creatinine in mg/dL or serum urea .10% of
the value of serum creatinine in mmol/L) may also reflect
dehydration.
Natriuretic peptides
Natriuretic peptides [NPs; brain natriuretic peptide (BNP) and
N-terminal pro-BNP (NT-proBNP)] are neurohormones specifi-
cally secreted from the cardiac chambers in response to volume
and pressure overload leading to increased wall tension. High pre-
discharge NP values are strong, independent predictors of death or
re-admission after hospitalization for AHF, and incremental to
other clinical and laboratory variables.74,75 Thus, measurement of
NPs prior to discharge can be useful in identifying patients at
high risk for adverse events. A decrease in initially high NPs
observed in patients with congestion before discharge may be a
useful indicator of a reduction in filling pressure.76 However, the
utility of NP levels may be limited by the fact that their production
and release may lag behind acute changes in haemodynamic
measurements.77 Increases in NP levels are non-specific and may
reflect cardiac stress including sepsis, pulmonary disease, and
renal dysfunction even when no important cardiac disease is
present. In this setting, they may be markers of cardiac stress
rather than cardiac disease. This may be why they are better as
markers of prognosis than accurate diagnostic tools. Importantly,
NPs cannot be used alone to assess congestion but must be eval-
uated as with most tests in the appropriate clinical context. A
patient with high NPs at discharge (NT-proBNP . 1500 pg/mL
and BNP. 300 pg/mL) should be considered at high risk of
death or re-admission. However, the increase in risk as NP
levels rise is linear and use of a single, precise cut-point is not
appropriate. Values are best used to describe low, medium, and
high risk. Adequately sized studies do not yet exist to provide
more precise direction.
Chest radiography
The absence of chest X-ray findings of HF (e.g. cardiomegaly, vas-
cular redistribution, and interstitial and alveolar oedema) does not
exclude a high PCWP. Radiographic signs of pulmonary congestion
are absent in 53% of the patients with PCWP of 16–29 mmHg and
in 39% of the patients with PCWP of ≥30 mmHg.51
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Dynamic manoeuvres
Orthostasis
The normal haemodynamic response in patients with normal LV
function and filling pressures when their position is changed from
sitting to standing is a slight reduction in blood pressure (by
4 mmHg systolic and 5 mmHg diastolic) and an increase in heart
rate.78 In these patients, significant volume depletion or blood loss
results in a reduction in preload and cardiac output, manifesting
in large changes in blood pressure (greater than equal to
220 mmHg systolic) and heart rate (≥10–30 b.p.m.), depending
on baseline conditions and the use of beta-blocking agents.
However, in many patients with HF and high filling pressures, ortho-
static postural changes may result in improved haemodynamics,
potentially leading to relief of subendocardial ischaemia, attenuation
of sphericity, and mitral regurgitation, and reductions in preload
leading to an increase in cardiac output.25 As a result, these patients
may actually have an increase in systolic blood pressure with ortho-
static changes. When these patients have lower filling pressures, the
orthostatic changes will not change their cardiac output and not have
the paradoxical postural increase in blood pressure.79 Therefore, in
patients with HF with an initial paradoxical increase in blood
pressure with orthostasis, documentation of lack of a blood pressure
increase may indicate a euvolaemic state. This observation cannot be
applied to patients with other forms of cardiomyopathy, such as
hypertrophic cardiomyopathy or aortic stenosis, where normal
cardiac output is dependent on elevated filling pressures. In addition,
blood pressure cannot be measured reliably in patients with atrial
fibrillation using standard instruments.
When measuring postural vital signs, clinicians should wait at
least 2 min before performing measurements in the supine pos-
ition, and at least 1 min before measuring vital signs in the
upright position in order to allow the postural haemodynamic
changes to take effect. Care should be taken to use a properly
sized blood pressure cuff and to keep the cuff at the level of the
heart.
A major limitation to the use of orthostasis for determining the
presence of congestion is that one must know whether the HF
patient has a dilated ventricle or other forms of systolic or diastolic
failure. Nevertheless, orthostatic changes are of practical impor-
tance because they provide a benchmark against which one may
measure volume status and diuretic response.
Valsalva manoeuvre
Although generally underutilized in clinical practice, assessment of
blood pressure in response to the Valsalva manoeuvre may have a
role as a non-invasive bedside tool to evaluate volume status.
Bedside sphygmomanometry can provide a qualitative assessment
of volume status, and commercially available arterial waveform
devices provide a rapid and reliable beat-to-beat measurement of
cardiovascular dynamics that can estimate LV filling pressures.
Studies have demonstrated a high correlation between the cardio-
vascular response to the Valsalva manoeuvre and invasively
measured ventricular filling pressures in HF patients.80,81 The
normal blood pressure response to the Valsalva manoeuvre is an
initial increase with the onset of straining caused by an acute increase
in intrathoracic pressure (Phase 1), followed by a sharp decrease to
below baseline levels as the straining is maintained caused by a
decreased venous return and compensatory increase in systemic
vascular resistance and heart rate (Phase 2).82 After the strain is
released, there is a short reduction in arterial pressure due to an
acute reduction in intrathoracic pressure (Phase 3), followed by an
overshoot in arterial pressure due to increased venous return
with a decrease in systemic vascular resistance and heart rate
(Phase 4). In patients with mild HF, Phases 1 through 3 are normal,
but Phase 4 is absent (‘absent overshoot’ pattern). In patients with
advanced HF, after Phase 1, the increase in blood pressure
remains elevated during the entire strain period, returning to base-
line after release in Phase 3 (‘square wave’ pattern). The mechanism
behind this abnormal response is the maintenance of LV filling from
increased central blood volume that maintains stroke volume,
despite changes in intrathoracic pressures.80,83
Bedside sphygmomanometry can assess normal and abnormal
responses to the Valsalva manoeuvre, as originally described in
1956.84 After the cuff is inflated and maintained at 15 mmHg
higher than systolic blood pressure, the Valsalva manoeuvre is per-
formed while Korotkoff sounds are auscultated over the brachial
artery. The normal response is when only Phases 1 and 4 are regis-
tered, ‘absent overshoot’ is when only Phase 1 is registered, and
the ‘square wave’ is when only Phases 1 and 2 are registered.85
This method has been shown to be clinically useful in ambulatory
patients; however, it is dependent on patient effort.86
Future directions
Echocardiography and portable
ultrasound
Echocardiography is the most commonly used non-invasive tool to
assess cardiovascular structure and function but may be misleading
in AHF. Compared with NPs, LVEF is a poor predictor of prognosis;
however, other echocardiographic parameters may be used to esti-
mate the severity of congestion.87 Right and left atrial pressures can
also be estimated by echocardiography in expert hands, although
with less certainty in AHF.70– 74 Estimation of right atrial pressure
can be performed using any two-dimensional echocardiography
platform by measuring the diameter of the inferior vena cava
(IVC).88 In a healthy state, IVC diameter collapses upon inspiration
and expands during expiration due to the changes in intrathoracic
pressure with respiration. High right atrial pressures dilate the IVC
and blunt this normal IVC collapsibility. Therefore, small, collapsible
IVCs as visualized by echocardiography represent low right atrial
pressures, whereas large, non-collapsible IVCs reflect high right
atrial pressures. A dilated, non-collapsible IVC was one of a few pre-
dictors of readmission after hospitalization for HF in a small obser-
vational study.89
Left atrial pressure can be estimated by observing diastolic
events using Doppler and tissue Doppler imaging. One of the ear-
liest events in diastolic and systolic dysfunction is the reduction in
myocardial velocity in early diastole and can be measured by the
E′-wave using tissue Doppler imaging. As filling pressures increase,
early mitral inflow velocities, as measured by the E-wave using
pulse-wave Doppler, also increase. The ratio of E/E′ has been
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found to correlate well with PCWP.90– 92 In addition, an elevated
E/E′ ratio has been shown to predict adverse outcomes in HF in
small series of patients in expert hands and is complementary to
such measurements as BNP and expert clinical assessment.93–95
However, patients with mitral regurgitation were excluded from
these early studies, and in recent studies, the correlation in this
patient subset may be less robust than previously reported.96
Ultrasonography of the lungs using an echocardiographic probe
is another potentially useful way to assess pulmonary congestion.
In patients with pulmonary congestion, images defined as ‘ultra-
sound lung comets’ can be visualized by scanning with cardiac
probes along the intercostal spaces.97 A correlation exists
between the number of ‘ultrasound lung comets,’ pulmonary con-
gestion demonstrated by radiographic signs, interstitial oedema
documented by computed tomography, extravascular lung water
measured by the indicator dilution technique, and PCWP.98,99
Although echocardiography is a simple method of estimating EF
and filling pressures, it is not practical to perform and repeat these
measurements on every patient admitted with HF. Portable ultra-
sound may have promise in routine and serial assessment of HF
patients.100
Thoracic impedance monitoring
Thoracic impedance measurement provided by an external or
implanted device has been investigated in recent years.95 Several
studies have shown that decreasing thoracic impedance correlates
with HF hospitalizations.19,101,102 There are studies ongoing to
determine the clinical effectiveness of outpatient monitoring of
thoracic impedance with the hope of decreasing HF hospitaliz-
ations and improving outcomes. Should these techniques prove
effective, many patients could be evaluated prior to hospital dis-
charge to confirm euvolaemia.103
Blood pool analysis
Another method of assessing volume status is blood volume analy-
sis. This technique uses radioisotopes tagged to red cells or
albumin to directly measure blood volume. It correlates with inva-
sive measurements of cardiac filling pressures in patients present-
ing with decompensated HF.104 –108 This technique has existed for
quite some time, but more clinical trials are needed before it is
used to use this to guide therapy.109
Grading congestion
The above measurements each have their strengths and weak-
nesses. Some measurements are only predictive of congestion in
the context of other congestion findings. Similarly, some measure-
ments predict congestion from right-sided HF, whereas others
predict congestion from left-sided HF or biventricular failure.
A systematic approach to grading congestion would be helpful in
initiating and following response to therapy. Previous scores have
used only clinical examination to evaluate congestion.34,110 We
propose that a combination of available measurements of congestion
be prospectively tested for their ability to predict re-hospitalization
after admission for AHF. Once this is established, therapy for fluid
removal could be adjusted with the goal of reducing the overall
amount of congestion, with re-hospitalization as the measured
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Grading congestion
Variable Score
21 0 1 2 3
Bedside assessment
Orthopnoeaa None Mild Moderate Severe/worst
JVP (cm) ,8 and no hepatojugular
reflux
8–10 or
hepatojugular
reflux
11–15 .16
Hepatomegaly Absent in the setting of
normal JVP
Absent Liver edge Moderate pulsatile
enlargement
Massive tender enlargement
extending to midline
Oedema None 1+ 2+ 3+/4+
Laboratory
Natriuretic peptides (one)
BNP ,100 100–299 300–500 .500
NT pro-BNP ,400 400–1500 1500–3000 .3000
Dynamic manoeuvres
Orthostatic
testing
Significant decrease in SBP or
increase in HR
No change in
SBP or HR
No difficulty Mild Moderate Severe/worst
6 min walk test .400 m 300–400 m 200–300 m 100–200 m ,100 m
Valsalva
manoeuvre
Normal response Absent overshoot
pattern
Square wave pattern
Congestion grade: ,1, none; 1–7, mild; 8–14, moderate; 15–20, severe. Oedema, in the absence of other cause of oedema.
aOrthopnoea: 0, absent; mild (use of one pillow); moderate (use of more than one pillow); severe, sleeps in an armchair on in a seated position.
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outcome (if the treatment is safe). Key elements in the measurement
of congestion include bedside assessment, laboratory analysis, and
dynamic manoeuvres, as outlined above and summarized in Table 3.
A point system is used to quantify the degree of congestion. We antici-
pate that this model will not be the one finally selected for regular
clinical use, but it provides a crucial starting point from which to
evolve. Ultimately, a revision of this score offers a new instrument
to direct both current and investigational therapies designed to opti-
mize volume status during and after hospitalization.
Summary
Although congestion, not a low cardiac output, is the main cause
for hospitalization, many HF patients are discharged with persistent
signs and symptoms of congestion and/or a high LV filling pressure.
Available data suggest that a pre-discharge clinical assessment of
congestion is often not performed, and even when it is performed,
it is not done systematically. We have reviewed a variety of strat-
egies to assess congestion which should be considered in the care
of patients admitted with HF. These strategies expand upon guide-
line recommendations for optimizing volume status and inpatient
HF performance measures, by suggesting a routine assessment of
congestion and a pre-discharge scoring system.
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